|
SUDA becomes Arovella Therapeutics
|
22 October 2021 at 8:45am
|
|
Chile Ministry of Health Approval Granted for ZolpiMist
|
21 October 2021 at 10:30am
|
|
Results of General Meeting
|
14 October 2021 at 2:15pm
|
|
GM presentation
|
14 October 2021 at 9:55am
|
|
Appendix 4G and Corporate Governance Statement 2021
|
30 September 2021 at 4:25pm
|
|
Annual Report to shareholders
|
30 September 2021 at 4:25pm
|
|
Notice of Extraordinary General Meeting/Proxy Form
|
15 September 2021 at 10:35am
|
|
Investor Presentation
|
7 September 2021 at 9:15am
|
|
Dr John Maher Appointed to SUDA iNKT Cell Therapy SAB
|
3 September 2021 at 9:25am
|
|
Preliminary Final Report
|
31 August 2021 at 11:10am
|
|
Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
|
26 August 2021 at 10:05am
|
|
SUDA signs Licence and Distribution Agreement with STADA
|
24 August 2021 at 11:10am
|
|
ZolpiMist Update
|
23 August 2021 at 3:55pm
|
|
iNKT cell therapy platform update
|
16 August 2021 at 10:15am
|
|
Initial Director's Interest Notice
|
12 August 2021 at 10:10am
|
|
Appointment of Dr Debora Barton as Non-Executive Director
|
10 August 2021 at 8:40am
|
|
SUDA appoints new cell and gene therapy manufacturing expert
|
2 August 2021 at 9:15am
|
|
SUDA to present at NWR Virtual Investor Conference
|
29 July 2021 at 10:15am
|
|
Quarterly Appendix 4C and Activities Report
|
26 July 2021 at 10:35am
|
|
Notification regarding unquoted securities - SUD
|
13 July 2021 at 6:15pm
|
|
Application for quotation of securities - SUD
|
29 June 2021 at 4:59pm
|
|
Proposed issue of securities - SUD
|
22 June 2021 at 4:35pm
|
|
Disclosure Document Prospectus $3.65m
|
22 June 2021 at 10:35am
|
|
Proposed issue of securities - SUD
|
22 June 2021 at 10:35am
|
|
SUDA Placement Raises $3.65m
|
22 June 2021 at 10:35am
|
|
Investor Webinar
|
18 June 2021 at 2:00pm
|
|
Investor Presentation incorporating iNKT Cell Platform
|
18 June 2021 at 1:05pm
|
|
SUDA Licenses a Novel iNKT Cell Therapy Platform
|
18 June 2021 at 10:25am
|
|
Trading Halt
|
18 June 2021 at 9:50am
|
|
Quarterly Appendix 4C and Activities Report
|
27 April 2021 at 8:45am
|
|
Anagrelide Project Update
|
7 April 2021 at 8:50am
|
|
Investor Presentation March 2021
|
30 March 2021 at 9:25am
|
|
Newsletter March 2021
|
29 March 2021 at 11:55am
|
|
Anagrelide Project Update
|
29 March 2021 at 8:55am
|
|
Appendix 3G
|
3 March 2021 at 5:05pm
|
|
Anagrelide Project Update
|
26 February 2021 at 9:10am
|
|
Appendix 4D & Interim Financial Half Year Report FY2021
|
26 February 2021 at 8:25am
|
|
Change of Director's Interest Notice
|
16 February 2021 at 5:10pm
|
|
Change of Director's Interest Notice
|
16 February 2021 at 5:10pm
|
|
Change of Director's Interest Notice
|
16 February 2021 at 5:00pm
|
|
Appendix 2A
|
16 February 2021 at 12:40pm
|
|
Zelira Therapeutics Feasibility Study Update
|
16 February 2021 at 8:45am
|
|
Results of General Meeting
|
29 January 2021 at 3:55pm
|
|
GM presentation
|
29 January 2021 at 9:40am
|
|
Quarterly Appendix 4C and Activities Report
|
25 January 2021 at 9:10am
|
|
Zolpimist Update
|
25 January 2021 at 8:50am
|
|
Suda Update
|
18 January 2021 at 8:55am
|
|
Notice of EGM and Proxy form
|
24 December 2020 at 8:45am
|
|
Placement Offer Completed and Appendix 2A
|
22 December 2020 at 11:25am
|
|
Proposed issue of Securities - SUD
|
22 December 2020 at 8:40am
|
